Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

immucillin H

Known as: 1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-iminoribitol, Forodesine, ImmH cpd 
A substance being studied in the treatment of some types of leukemia and lymphoma. It is a type of purine nucleoside phosphorylase (PNP) inhibitor.
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

BCX1777

Broader (2)

Purine NucleosidesPyrimidinones
forodesine hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Older and new purine nucleoside analogs for patients with acute leukemias.
Purine nucleoside analogs (PNAs) compose a class of cytotoxic drugs that have played an important role in the treatment of… Expand
Is this relevant?
Review
2012
Review
2012
Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphomas (CTCLs) are a rare group of mature T-cell lymphomas presenting primarily in the skin. The most common… Expand
  • figure 1
  • table I
  • table II
Is this relevant?
2012
2012
Serum 25-dihydroxyvitamin D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma.
impact of B-cell immunodeficiency in cases of PNP deficiency and is probably explained by the complete lack of PNP enzyme… Expand
  • table I
  • figure 1
Is this relevant?
2010
2010
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
Forodesine, a purine nucleoside phosphorylase inhibitor, displays in vitro activity in chronic lymphocytic leukemia (CLL) cells… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2009
Review
2009
How I treat mycosis fungoides and Sézary syndrome.
The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2005
2005
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
  • figure 3
Is this relevant?
2003
2003
Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir.
In human, purine nucleoside phosphorylase (HsPNP) is responsible for degradation of deoxyguanosine and genetic deficiency of this… Expand
Is this relevant?
2002
2002
Purine-less Death in Plasmodium falciparumInduced by Immucillin-H, a Transition State Analogue of Purine Nucleoside Phosphorylase*
Plasmodium falciparum is responsible for the majority of life-threatening cases of malaria. Plasmodia species cannot synthesize… Expand
Is this relevant?
2001
2001
Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Patients with purine nucleoside phosphorylase (PNP) deficiency present a selective T-cell immunodeficiency. Inhibitors of PNP are… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes
Transition-state theory has led to the design of Immucillin-H (Imm-H), a picomolar inhibitor of purine nucleoside phosphorylase… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE